
Healthcare Monthly


December 2018




Healthcare Headline Transactions




Note: All premium data calculated is based on the closing market value one day prior to announcement





LTM Revenue Growth



Enterprise Value / LTM EBITDA







Selected Biotech. / Pharmaceutical Transactions

Target	Acquiror	Target Description
Asterias Biotherapeutics, Inc.	BioTime, Inc.	Asterias Biotherapeutics, Inc. develops cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies Transaction Value: \$51 million Transaction Premium: 40.7%
Elto Pharma, Inc.	Coeptis Pharmaceuticals, Inc.	Elto Pharma, Inc. develops eltoprazine, an oral small molecule 5HT1A/1B for the treatment of Parkinson's disease levodopa- induced dyskinesia
Euromed S.A.	Dermapharm Holding SE	Euromed S.A. produces herbal extracts and natural active substances for pharmaceutical, health, food and cosmetic industries

Selected Healthcare Services Transactions

Target	Acquiror	Target Description
MatrixCare, Inc.	ResMed Operations Inc.	MatrixCare, Inc. provides clinical, financial and operations software solutions for the skilled nursing, senior living and long term care industries Transaction Value: \$750 million
Servicios Veterinarios Hospitalarios SL	TA Associates Management, L.P.	Servicios Veterinarios Hospitalarios SL owns and operates veterinary clinics
BioAgilytix Labs, LLC	Cobepa S.A.	BioAgilytix Labs, LLC operates as a bioanalytical contract research organization (CRO) that develops novel therapeutic biologics and biosimilars

Selected Medical Device Transactions

milestones Revenue: 7.5x

Revenue: 4.0x EBITDA: 25.0x **Target Description**

Paradigm Spine, LLC designs, develops and markets solutions

Transaction Value: \$150 million upfront, up to \$150 million in

ChoiceSpine, LP manufactures and markets spinal products to orthopedic and neurosurgeon specialists for the treatment of

Bioquell plc manufactures bio-decontamination and containment equipment, and related products Transaction Value: \$173 million

spinal disorders and deformities in patients

for the treatment of spinal diseases

Selected Life Sciences / Diagnostics Transactions

Target	Acquiror	Target Description
Pacific Biosciences of California, Inc.	Illumina, Inc.	Pacific Biosciences of California, Inc. designs, develops and manufactures sequencing systems Transaction Value: \$1,283 million Transaction Premium: \$79.8% Revenue: 13.9x
Exocell, Inc.	Ethos Biosciences, Inc.	Exocell, Inc. provides products and assays for clinical diagnostics, clinical investigation, laboratory research, reagents and reference standards
Affinity Biologicals Inc.	Precision BioLogic Inc.	Affinity Biologicals Inc. manufactures research and diagnostic products in the fields of hemostasis, thrombosis and coagulation

Note: All premium data calculated based on the closing market value one day prior to announcement

Selected TM Capital Healthcare Experience





Target

Bioquell plc

ChoiceSpine, LP

Paradigm Spine, LLC

Acquiror

RTI Surgical, Inc.

Ecolab U.S. 2 Inc.

Altus Capital Partners

James I. McLaren Managing Director jmclaren@tmcapital.com (212) 809-1414



TM Capital's Healthcare Contacts

Michael S. Goldman Managing Director mgoldman@tmcapital.com (212) 809-1419



Paul R. Smolevitz Managing Director psmolevitz@tmcapital.com (212) 809-1416



ATLANTA BOSTON NEW YORK